Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   Potent dual block to HIV-1 infection using lentiviral vectors expressing fusion inhibitor peptide mC46- and Vif-resistant APOBEC3G
  2. Frankenberry,Krista; Ojha, Chet R; Hermann, Kip J; Hu,Wei-Shau; Torbett, Bruce E; Pathak,Vinay
  3. Molecular Therapy. Nucleic Acids. 2023, Sep 12; 33: 794-809.
  1. 2.   HIV-1 VIF and human APOBEC3G interaction directly observed through molecular specific labeling using a new dual promotor vector
  2. Myint,Wazo; Schiffer, Celia A; Matsuo,Hiroshi
  3. Journal of Magnetic Resonance (San Diego, Calif. : 1997). 2022, Apr 26; 339: 107230.
  1. 3.   APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma
  2. Faden, Daniel L; Kuhs, Krystle A Lang; Lin, Maoxuan; Langenbucher, Adam; Pinheiro, Maisa; Yeager,Meredith; Cullen,Michael; Boland,Joseph; Steinberg,Mia; Bass,Sara; Lewis, James S; Lawrence, Michael S; Ferris, Robert L; Mirabello, Lisa
  3. Viruses. 2021, Aug 23; 13(8):
  1. 4.   Interactions of APOBEC3s with DNA and RNA
  2. Maiti, Atanu; Hou, Shurong; Schiffer, Celia A.; Matsuo,Hiroshi
  3. Current opinion in structural biology. 2021, Apr; 67: 195-204.
  1. 5.   Crystal structure of a soluble APOBEC3G variant suggests ssDNA to bind in a channel that extends between the two domains
  2. Maiti,Atanu; Myint,Wazo; Frankenberry,Krista; Hou, Shurong; Kanai,Tapan; Balachandran,Vanivilasini; Sierra Rodriguez, Christina; Tripathi, Rashmi; Kurt Yilmaz, Nese; Pathak,Vinay; Schiffer, Celia A; Matsuo,Hiroshi
  3. Journal of molecular biology. 2020, Nov 20; 432(23): 6042-6060.
  1. 6.   GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
  2. Gara, Sudheer Kumar; Tyagi, Monica Varun; Patel, Dhaval Thakkur; Gaskins, Kelli; Lack,Justin; Liu, Yi; Kebebew, Electron
  3. Oncotarget. 2020, Sep 08; 11(36): 3354-3370.
  1. 7.   Structural Insights into APOBEC3-Mediated Lentiviral Restriction
  2. Delviks-Frankenberry, Krista A.; Desimmie, Belete A.; Pathak,Vinay
  3. Viruses. 2020, JUN; 12(6):
  1. 8.   Immune gene expression profiling reveals heterogeneity in luminal breast tumors
  2. Zhu, Bin; Tse, Lap Ah; Wang,Difei; Koka, Hela; Zhang, Tongwu; Abubakar, Mustapha; Lee, Priscilla; Wang, Feng; Wu, Cherry; Tsang, Koon Ho; Chan, Wing-Cheong; Law, Sze Hong; Li, Mengjie; Li, Wentao; Wu, Suyang; Liu, Zhiguang; Huang, Bixia; Zhang, Han; Tang, Eric; Kan, Zhengyan; Lee, Soohyeon; Park, Yeon Hee; Nam, Seok Jin; Wang, Mingyi; Sun, Xuezheng; Jones, Kristine; Zhu,Bin; Hutchinson,Amy; Hicks,Belynda; Prokunina-Olsson, Ludmila; Shi, Jianxin; Garcia-Closas, Montserrat; Chanock, Stephen; Yang, Xiaohong R
  3. Breast cancer research : BCR. 2019, Dec 19; 21(1): 147.
  1. 9.   Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
  2. Frankenberry,Krista; Ackerman, Daniel; Timberlake, Nina D; Hamscher, Maria; Nikolaitchik,Olga; Hu,Wei-Shau; Torbett, Bruce E; Pathak,Vinay
  3. Molecular therapy. Nucleic acids. 2019, Dec 6; 18: 1023-1038.
  1. 10.   Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
  2. Reid, Erin G.; Looney, David; Maldarelli, Frank; Noy, Ariela; Henry, David; Aboulafia, David; Ramos, Juan Carlos; Sparano, Joseph; Ambinder, Richard F.; Lee, Jeannette; Cesarman, Ethel; Yahyaei, Sara; Mitsuyasu, Ronald; Wachsman, William
  3. Blood advances. 2018, Dec 26; 2(24): 3618-3626.
  1. 11.   Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFß that is critical for Vif function.
  2. Desimmie, Belete; Smith, Jessica; Matsuo, Hiroshi; Hu, Wei-Shau; Pathak, Vinay
  3. Retrovirology. 2017, Mar 17; 14(1): 19.
  1. 12.   Severe Restriction of Xenotropic Murine Leukemia Virus-Related Virus Replication and Spread in Cultured Human Peripheral Blood Mononuclear Cells
  2. Chaipan, C.; Dilley, K. A.; Paprotka, T.; Delviks-Frankenberry, K. A.; Venkatachari, N. J.; Hu, W. S.; Pathak, V. K.
  3. Journal of Virology. 2011, May; 85(10): 4888-4897.
  1. 13.   P Body-Associated Protein Mov10 Inhibits HIV-1 Replication at Multiple Stages
  2. Burdick, R.; Smith, J. L.; Chaipan, C.; Friew, Y.; Chen, J. B.; Venkatachari, N. J.; Delviks-Frankenberry, K. A.; Hu, W. S.; Pathak, V. K.
  3. Journal of Virology. 2010, Oct; 84(19): 10241-10253.
  1. 14.   Vif of Feline Immunodeficiency Virus from Domestic Cats Protects against APOBEC3 Restriction Factors from Many Felids
  2. Zielonka, J.; Marino, D.; Hofmann, H.; Yuhki, N.; Lochelt, M.; Munk, C.
  3. Journal of Virology. 2010, Jul; 84(14): 7312-7324.
  1. 15.   APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms
  2. Mbisa, J. L.; Bu, W.; Pathak, V. K.
  3. Journal of Virology. 2010, May; 84(10): 5250-5259.
  1. 16.   Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development
  2. Smith, J. L.; Bu, W.; Burdick, R. C.; Pathak, V. K.
  3. Trends in Pharmacological Sciences. 2009, Dec; 30(12): 638-646.
  1. 17.   Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA
  2. Friew, Y. N.; Boyko, V.; Hu, W. S.; Pathak, V. K.
  3. Retrovirology. 2009 6 AR 56
  1. 18.   A macaque model of HIV-1 infection
  2. Hatziioannou, T.; Ambrose, Z.; Chung, N.; Piatak, M.; Yuan, F.; Trubey, C. M.; Coalter, V.; Kiser, R.; Schneider, D.; Smedley, J.; Pung, R.; Gathuka, M.; Estes, J. D.; Veazey, R. S.; KewalRamani, V. N.; Lifson, J. D.; Bieniasz, P. D.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2009 106(11): 4425-4429 DI 10.1073/pnas.
  1. 19.   Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance
  2. Jern, P.; Russell, R. A.; Pathak, V. K.; Coffin, J. M.
  3. Plos Pathogens. 2009 5(4):
  1. 20.   Guidelines for Naming Nonprimate APOBEC3 Genes and Proteins
  2. Larue, R. S.; Andresdottir, V.; Blanchard, Y.; Conticello, S. G.; Derse, D.; Emerman, M.; Greene, W. C.; Jonsson, S. R.; Landau, N. R.; Lochelt, M.; Malik, H. S.; Malim, M. H.; Munk, C.; O'Brien, S. J.; Pathak, V. K.; Strebel, K.; Wain-Hobson, S.
  3. Journal of Virology. 2009 83(2): 494-497.
  1. 21.   Species-specific Inhibition of APOBEC3C by the Prototype Foamy Virus Protein Bet
  2. Perkovic, M.; Schmidt, S.; Marino, D.; Russell, R. A.; Stauch, B.; Hofmann, H.; Kopietz, F.; Kloke, B. P.; Zielonka, J.; Strover, H.; Hermle, J.; Lindemann, D.; Pathak, V. K.; Schneider, G.; Lochelt, M.; Cichutek, K.; Munk, C.
  3. Journal of Biological Chemistry. 2009 284(9): 5819-5826.
  1. 22.   APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA
  2. Russell, R. A.; Moore, M. D.; Hu, W. S.; Pathak, V. K.
  3. Retrovirology. 2009 6: 16.
  1. 23.   Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif
  2. Russell, R. A.; Smith, J.; Barr, R.; Bhattacharyya, D.; Pathak, V. K.
  3. Journal of Virology. 2009 83(4): 1992-2003.
  1. 24.   Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F
  2. Russell, R. A.; Pathak, V. K.
  3. Journal of Virology. 2007, Aug; 81(15): 8201-8210.
  1. 25.   Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions
  2. Xu, H. Z.; Chertova, E.; Chen, J. B.; Ott, D. E.; Roser, J. D.; Hu, W. S.; Pathak, V. K.
  3. Virology. 2007, Apr; 360(2): 247-256.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel